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‐ Tyrosol (Tyr) is converted into hydroxytyrosol (OHTyr) in vivo in humans
‐ P450 enzymes CYP2A6 and CYP2D6 mediate this bioconversion
‐ Ingestion of Tyr and its conversion into OHTyr improve endothelial function
‐ Tyr and its OHTyr conversion improve HDL cholesterol, vasodilatory, and 
inflammatory markers




Introduction: The simple phenol hydroxytyrosol (OHTyr) has been associated with the 
beneficial health effects of extra virgin olive oil. Pre-clinical studies have identified Tyr 
hydroxylation, mediated by cytochrome P450 isoforms CYP2A6 and CYP2D6, as an 
additional source of OHTyr. 
Aim: We aimed to (i) confirm Tyr to OHTyr bioconversion in vivo in humans, (ii) to 
assess the cardiovascular benefits of this bioconversion, and (iii) determine their 
interaction with a polygenic activity score (PAS) from CYP2A6 and CYP2D6 genotypes.
Methods: Randomized, crossover, controlled study. Individuals at cardiovascular risk 
(n=33) received: white wine (WW) (females 1, males 2 standard drinks/day), WW plus 
Tyr capsules (WW+Tyr) (25mg Tyr capsule, one per WW drink), and water (control) ad 
libitum. Participants were classified by a PAS as low versus normal activity metabolizers. 
Results:  OHTyr recovery following WW+Tyr was higher than after other interventions 
(P<0.05). Low PAS individuals had lower OHTyr/Tyr ratios compared to individuals 
with normal PAS. WW+Tyr improved endothelial function, increased plasma HDL-
cholesterol and antithrombin IIII, and decreased plasma homocysteine, endothelin 1, and 
CD40L, P65/RELA, and CFH gene expression in peripheral blood mononuclear cells 
(p<0.05). Combining Tyr capsule(s) with WW abolished the increase in iNOS, eNOS, 
VEGFA, and CHF expressions promoted by WW (p<0.05). 
Conclusions: Tyr, and its partial biotransformation into OHTyr, promoted cardiovascular 
health-related benefits in humans after dietary doses of Tyr. The study design allowed the 
health effects of individual phenols to be singled out from the dietary matrix in which 
they are naturally found.
5
Graphical Abstract
Keywords: CYP2A6, CYP2D6, Endothelial function, Hydroxytyrosol, Tyrosol, Wine  
Abbreviations




CFH, complement factor H
CVD, cardiovascular disease
CYP2A6, cytochrome P450 2A6 isoform
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CYP2D6, cytochrome P450 2D6 isoform
EFSA, European Food Safety Authority
ET1, endothelin 1
Hcy, homocysteine
HDL-c, high density lipoproteins cholesterol
HVAL, homovanillic alcohol
LA, low activity metabolizers
NA, normal activity metabolizers
eNOS, endothelial nitric oxide synthase
iNOS, inducible nitric oxide synthase
OHTyr, hydroxytyrosol
PAS, polygenic activity score
PBMC, peripheral blood mononuclear cells
p65/RELA, transcription factor p65
RHI, reactive hyperemia index
Tyr, tyrosol
VEGFA, vascular endothelial growth factor A
VOO, virgin olive oil
WW, white wine 
WW+Tyr, white wine plus tyrosol capsules
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1.Introduction
Hydroxytyrosol (OHTyr), a prototypic virgin olive oil (VOO) phenolic 
compound, has strong antioxidant activity. Pre-clinical studies have attributed to OHTyr 
anti-inflammatory, anti-proliferative, pro-apoptotic, anti-microbial, and neuroprotective 
properties [1]. Several clinical trials have shown that OHTyr-rich VOO, alone or in 
combination with a Mediterranean dietary (MeDiet) pattern, improves lipid profile, 
protects against lipid oxidation, and prevents primary cardiovascular disease (CVD) 
outcomes [2,3]. In the EUROLIVE study, [2] olive oil phenols were shown to prevent 
LDL oxidation in vivo in humans. In November 2011, the European Food Safety 
Authority (EFSA) released a claim concerning the benefits of the daily ingestion of 5 mg 
or more of OHTyr and its derivates, e.g. tyrosol (Tyr), from olive oil on protecting low 
density lipoproteins (LDL) from oxidation [4]. 
OHTyr direct antioxidant activity is attributed to its ortho-diphenol moiety, 
capable of scavenging free radicals in vitro. Because free radical activities should play a 
central role in the prevention of LDL oxidation by olive oil phenols, further studies have 
investigated their radical scavenging capacities. OHTyr and other olive oil phenols were 
tested in the AAPH(2,2-azobis(2-amidinopropane) dihydrochloride))-induced oxidation 
model. The inhibition of lipids oxidation was assumed to be related to a reduction of the 
AAPH-derived initiating radicals. Olive oil phenols were shown to be efficient 
scavengers of hydrophilic peroxyl radicals with a long-lasting antioxidant effect owing to 
the residual activity of some of their oxidation products (oligomer formation with the 
addition of water molecules) [5]. The radical-scavenging capacities (hydrogen donation 
abilities) of Tyr and OHTyr were also investigated using the 2,2-diphenyl-1-picryl-
hydrazyl-hydrate (DPPH) assay. The 24-h kinetics of DPPH radical scavenging 
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(percentage of remaining DPPH) showed that OHTyr appeared to be a stronger antiradical 
scavenger than Trolox whereas TYR was found to be practically inactive [6].
Nevertheless, equivalent antioxidant effects in vivo are limited by bioavailability, 
concentration and location of the antioxidant in cells. However free radical scavenging 
cannot be discounted in the gut where concentrations of OHTyr after food intake are 
sufficiently high. Therefore, Forman et al (2014) stated that the most likely effect of the 
so-called nutritional antioxidants would be mediated by a process called para-hormesis; 
by inducing the endogenous antioxidant mechanism [7]. Polyphenols and polyphenol rich 
food, such as rich-phenolics olive oil, modulate paraoxonase 1(PON1) activity and 
expression [8,9]. Also polyphenols alter the expression of genes underlying 
atherosclerosis- and cancer-related pathways [10], and olive oil polyphenols enhance the 
expression of cholesterol efflux related genes in vivo in humans [11].
Both wine and VOO, two characteristic components of the MeDiet, are sources of 
OHTyr and Tyr [4,12].  Within the framework of the PREDIMED (Prevención con Dieta 
Mediterránea) Study, we previously reported 1) a direct dose-dependent association 
between OHTyr urinary concentrations and wine or alcohol consumption in individuals 
at high risk of cardiovascular diseases (CVD) [13], and 2) an independent association 
between high urinary concentrations of 3-O-methyl-hydroxytyrosol (HVAL), a OHTyr 
biological metabolite, and a lower risk of CVD and total mortality in CVD risk individuals 
[14]. In addition, in previous work [15–17],  we have shown that alcohol and red wine 
could promote di novo OHTyr generation in vivo in humans. We identified alterations in 
dopamine and tyramine oxidative metabolism, as well as an increased Tyr bioavailability 
due to ethanol, as mechanisms involved [17]. Results from our animal studies suggested 
biotransformation of Tyr to OHTyr as another related mechanism. In in vitro enzymatic 
9
studies in human liver samples identified the genetically polymorphic isoenzymes of 
cytochrome P450, CYP2A6, and CYP2D6, as involved in the biotransformation of Tyr 
into OHTyr [18]. CYP2A6 and CYP2D6 enzymatic activities have extensive inter-
individual and world population variation, primarily due to genetic variation. Although 
the health benefits of OHTyr ingestion in vivo in humans have been investigated [19], 
those of Tyr, per se, are at present unknown.
In this context, we performed a randomized, crossover, controlled trial in 
cardiovascular risk individuals with white wine, white wine plus Tyr capsules, and water 
acting as control. Our primary hypothesis was that the Tyr ingested would be bio-
transformed into OHTyr and together they would promote benefits on cardiovascular risk 
in humans. Our secondary hypothesis was that these processes would be modulated by 
the different genotypic profiles for CYP2A6 and CYP2D6. 
2. Experimental Section
2.1. Wine and Capsule Characteristics 
The white wine used in the experiments (12.5 % Alc. Vol., Bach Viña Extrísimo 
Blanco Seco 2016) was provided by the Codorniu Raventós Group (Barcelona, Spain). 
Tyr content (10.4 ± 0.6 mg/L) and that of OHTyr (1.3 ± 0.1 mg/L) was quantified by 
liquid chromatography coupled to tandem mass spectrometry (HPLC/MS/MS). Gelatin 
white opaque capsules containing 25 mg Tyr/unit were produced by the manufacturing 
department of the Jordi Cabezas Pharmacy (Barcelona, Spain). 
2.2. Study Population
Recruitment was carried out through a volunteer center database, primary 
healthcare centers, and word of mouth, starting on January 2016 and finishing on 
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December 2017. Inclusion criteria included being at high risk for coronary heart disease 
(CHD) with 3 or more risk factors. Inclusion and exclusion criteria are described in Data 
in Brief [20]. Subjects were interviewed to exclude concomitant medical conditions, and 
they underwent a general physical examination, laboratory tests, and a 12-lead ECG. The 
study was conducted in accordance with the Helsinki Declaration and approved by the 
local Ethical Committee (CEIm-Parc de Salut Mar) and registered in ClinicalTrials.gov 
database (NCT02783989). Written informed consent to participate was obtained prior to 
any study-related procedure. 
2.3. Study Design
A randomized, crossover, controlled study was performed at the Clinical Research 
Unit of the Hospital del Mar Medical Research Institute (IMIM, Barcelona, Spain). 
Participants were randomly assigned to one of six orders of administration to receive: 
water (control), white wine (WW), and WW plus tyrosol capsules (WW+Tyr) [20]. 
Participants were randomly allocated to the three types of intervention, through a 
computerized block-randomization method for sequence generation, by an independent 
statistician. Intervention periods lasted for four weeks preceded by three week wash-out 
periods in which participants were requested to avoid additional sources of alcohol, and 
to follow a low-phenol content diet [20]. In the WW periods, women ingested one glass 
of WW (135 mL, 13.5 g of alcohol, 1.4 mg of Tyr, and 0.2 mg of OHTyr), whereas males 
ingested two glasses of WW (270 mL, 27 g of alcohol, 2.8 mg of Tyr, and 0.4 mg of 
OHTyr). WW was ingested during meals; women drank one glass at lunch time while 
men drank one glass at lunch time and another glass at dinner time. In the WW+Tyr 
periods, participants ingested the same amount of WW as described above but in 
combination with capsules containing 25 mg Tyr: 2 for men (50 mg), and 1 (25 mg) for 
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women. During the control intervention subjects were only allowed to drink water (no 
alcohol, wine, or supplemented Tyr or OHTyr). The reason for different WW doses for 
men and women was in order to follow the American Heart Association (AHA) 
guidelines, which limit alcohol consumption to one drink per day in women and two in 
men, preferably taken at meals [21]. The doses of wine administered are within those 
recommended by the AHA, and that of Tyr, 25 to 50 mg/day, within the range of its 
maximal content per liter in red and fortified wines (e.g. sherry) (http://phenol-
explorer.eu/contents/polyphenol/673).
A 24 h food recall was performed to assess dietary intake before and after each 
intervention period. Physical activity was recorded at the beginning and end of the study 
and assessed by the Minnesota Leisure Time Physical Activity Questionnaire, validated 
for the Spanish population [22]. A general physical examination, and routine urine, blood 
chemical and hematological analyses, were performed at the beginning and end of the 
study.  Blood and 24h-urine samples were collected at fasting state before and after each 
intervention period. Blood was collected into 10 mL tubes containing EDTA and 
centrifuged (1700g, 15 min, 4 °C), and plasma and buffy coat samples were then isolated. 
Peripheral blood mononuclear cells (PBMC) were isolated using a Vacutainer Cell 
Preparation Tube (CPT™) and kept for RNA extraction. Plasma, urine, and PBMC 
samples were frozen at -80 °C until analysis. Genomic DNA isolation from buffy coat 
was performed with QIAamp DNA Blood Midi Kit (Qiagen, Dusseldorf, Germany).
2.4 Compliance biomarkers
The urinary concentrations of Tyr and OHTyr metabolites were determined from 
samples collected before and after each intervention following a validated methodology 
[20]. Total Tyr and OHTyr were obtained from the sum of their metabolites. 24 h-Urinary 
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concentrations of ethyl glucuronide, measured by HPLC/MS/MS, were assessed as a 
marker of alcohol consumption [23] .  
2.5. Genotyping 
Volunteers were genotyped for different allelic variants of CYP2A6 and CYP2D6 
using TaqMan genotyping assays (Applied Biosystems, Foster City, CA, USA) [20]. 
Tested allelic variants were categorized into: non-functional (CYP2A6 *2, *4; CYP2D6 
*4,*5); decreased function (CYP2A6 *9,*12; CYP2D6 *9,*10,*11); functional (CYP2A6 
*1; CYP2D6 *1,*2,*35); and increased function (CYP2A6 *1xN; CYP2D6 
*1xN,*2xN,*35xN). CYP2D6 gene duplications were further confirmed by… A score of 
0, 0.5, 1 or 2 was assigned for the presence of each allele [20]. For each enzyme, an 
activity score was assigned to each volunteer according to the alleles identified,  based on 
the method described by Gaedigk et al [24]. A pooled polygenic activity score (PAS) was 
calculated by adding the two enzyme activity scores together. According to their PAS, 
individuals were placed into three groups of phenotype activity: low activity (LA), normal 
activity (NA), and rapid activity (RA) groups.
2.6. Primary Outcomes
Endothelial function was assessed before and after interventions by monitoring 
endothelium-mediated changes (reactive hyperemia index, RHI) in the digital pulse 
waveform, known as the Peripheral Arterial Tone (PAT) signal (EndoPAT 2000; Itamar 
Medical Inc., Caesarea, Israel). The hyperemic reactivity index measured by EndoPAT 
2000 has been shown to predict cardiovascular disease [25].  EndoPAT 2000 also provides 
the augmentation index (AI), a measurement of arterial stiffness via pulse-wave analysis. 
Measurements were performed by a trained professional with the participants in resting 
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supine conditions, in a quiet room, at a constant temperature, after 10 minutes of 
stabilization [20].
2.7. Secondary Outcomes
2.7.1. Cardiovascular Risk Biomarkers 
All analyses were carried out before and after interventions, and samples from the 
same individual were analyzed in the same analytical run. Plasma glucose, triglycerides, 
total and HDL cholesterol (HDL-c), antithrombin III (ATIII), and dimer D were measured 
by automated enzymatic methods. LDL cholesterol was calculated by the Friedewald 
formula whenever triglycerides were inferior to 300 mg/dL. Serum high-sensitivity C 
reactive protein (hs-CRP) was determined by immunoturbidimetry (Horiba, Montpellier, 
France). Homocysteine (Hcy) in plasma was measured by gas chromatography-mass 
spectrometry (GC-MS) after liquid-liquid extraction. Nitrites and nitrates in plasma were 
determined by a colorimetric kit (Cayman Chemical, Michigan, USA). Endothelin 1 
(ET1) and plasminogen activator inhibitor-1 (PAI-1) were measured in plasma by ELISA 
(Invitrogen, California, USA; and Affymetrix, California, USA, respectively). 
2.7.2. Gene Expression 
On the basis of their relationship with endothelial health and atherosclerosis, and 
the available data of gene expression response after VOO ingestion [11,26], several 
candidate genes were selected. Gene expression was measured, before and after 
interventions, by a real-time polymerase chain reaction (See in Boronat et al., 2019 [20]).
2.8. Sample Size and Power Analyses
A total sample of 32 participants would allow at least 80% power to detect a 
statistically significant difference among groups of 0.205 units in the RHI measurement, 
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assuming a dropout rate of 5% and type I error of 0.005 (2-sided). The standard deviation 
of the measurement was assumed 0.4 [25].   
2.9. Statistical Analyses 
Normality of continuous variables was assessed by normal probability plots and 
data were log transformed when required. Intra-treatment comparisons were assessed by 
Student’s t test for paired samples. Comparisons among treatments were made by an 
ANOVA for repeated measures adjusted for age, gender, smoking, AAS medication, and 
baseline concentrations. In the case of lipids an additional adjustment for LDL cholesterol 
values at the beginning of the study was performed. A general linear model was used to 
assess linear and quadratic trends. For the post-hoc pairwise comparison, the Tuckey test 
was used. Statistical analyses were performed with R (R Foundation for Statistical 
Computing, Vienna, Austria), version 3.0.2., and R package multcomp. Significance was 
defined as p < 0.05. 
3.Results
3.1. Study Participants
From the 192 subjects assessed for eligibility, 157 were excluded [20]. The 
remaining 33 participants (21 men and 12 women) were randomly allocated to 
interventions, and 32 participants completed the study (Figure 1). Baseline characteristics 
of participants are described elsewhere [20]. Briefly, participants’ mean age was 65.3 ± 
6.2 years with a mean BMI of 32.6 ± 4.2 kg/m2. Main clinical features were 
overweight/obesity (97.0%), hypertension (84.8%), and dyslipidemia (75.6%). No 
differences in baseline characteristics were observed among the sequence of 
administration groups with the exception of LDL cholesterol which was higher (157 ± 24 
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mg/dL) in sequence 3 than in sequence 5 (98 ± 32 mg/dL). Thus, lipid variables were 
adjusted by LDL cholesterol in the statistical analyses. No changes in the level of physical 
activity were observed from the beginning to the end of the study in any group. No dietary 
differences were observed among interventions [20]. On the basis of the polygenic 
activity score (PAS), 11 individuals were categorized as low (LA, PAS range: 1-2.5), 19 
as normal (NA, PAS range: 3-4), and 2 as rapid (RA, PAS range = 5) activity 
metabolizers. Due to their low number, RAs were excluded for analyses. Age and gender 
were equally distributed among the three groups. 
Figure 1. Flow chart of the study
3.2. Compliance Biomarkers and Conversion of Tyrosol in Hydroxytyrosol
Changes in the 24h urinary recoveries of total Tyr and OHTyr in each treatment 
group are shown in Figure 2. Urinary Tyr and OHTyr increased in a dose-related manner 
with increasing Tyr content of the beverage administered, (p<0.001 and p=0.042, 
respectively for linear trend). Baseline values of ethyl-glucuronide, and those after water 
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treatment, were undetectable (i.e. below 4.5 nmol/mL based on assay detection limits). 
Ethyl-glucuronide urinary total excretion after WW intervention was 1.61 ± 1.11 µmol, 
and 2.18 ± 1.64 µmol following WW+Tyr.
Figure 2. Changes (mean± SEM) in 24h-urinary recovery of tyrosol and hydroxytyrosol 
metabolites after interventions. Total tyrosol accounted and total OHTyr correspond to 
the molar sum of their respective quantified metabolites. WW, white wine; WW+Tyr, white 
wine plus tyrosol (Tyr) capsules; * p<0.05, † p <0.001 versus water; ‡ p <0.05, ¥,  p <0.001 
versus WW
3.3 Interaction between PAS, Tyr and OHTyr metabolism
Figure 3 shows Tyr and OHTyr recoveries following WW+Tyr according to the 
PAS categories. Comparisons were adjusted to the administered dose of Tyr. The LA 
group presented higher recoveries of urinary total Tyr compared to NA one (p =0.021). 
Conversely, OHTyr metabolite recovery was higher in NA compared to LA (p=0.115).  
As expected OHTyr/Tyr ratio were higher in NA compared to LA (p =0.025).
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Figure 3. Phenotype interaction with Tyr and OHTyr metabolites following WW+Tyr: 
recovery of Tyr (A), recovery of OHTyr (B) standardized by Tyr dose administered. Data 
expressed as median and percentile 10-90th, Between-group comparison: * p< 0.05, ** 
p< 0.01.
Figure 4 shows the positive correlation between PAS and OHTyr/Tyr ratio (r= 
0.448; p=0.011). These associations were only found using the PAS including both 
enzymes, and not when analyzed alone for CYP2A6 or for CYP2D6 genotype activity 
scores separately. 
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Figure 4. Correlation between the polygenic activity score and the OHTyr/Tyr ratio. 
Broken lines indicate separation of low, normal and rapid activity groups. The 
determination coefficient has been assessed excluding individuals from the rapid activity 
group. 
3.4. Primary Outcomes
Table 1 shows the changes in the reactive hyperemia index (RHI) and 
augmentation index (AI) after each intervention. One volunteer had skin petechiae the 
first time the ENDOPAT test was performed and endothelial function was not measured 
in this subject, thus only 31 participants were assessed. RHI increased after the WW+Tyr 
intervention compared to its baseline (p=0.048), remaining significant only in men 
(p=0.041) when analyses were stratified by gender. When assessing the PAS-genotype 
interaction, RHI increased after the WW+Tyr intervention compared to its baseline 
(p=0.020) only among the LA group, the increase was significant versus changes in the 
WW intervention (p=0.040). AI decreased significantly after WW+Tyr compared to 
changes in control water intervention (p=0.047) but was not significant when stratified 
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by gender. When assessing the PAS-genotype interaction, the decrease in AI was 
significant versus changes in the control group in the case of the LA group (p=0.007).
Table 1. Changes in endothelial function after interventions
Intervention
p value for WW+TyrControl WW WW+Tyr vs Control vs WW
Reactive hyperemia index (AU)
All participants 0.04 ± 0.40 0.03 ± 0.49 0.17 ± 0.47* 0.521 0.309
 Women 0.03 ± 0.54 - 0.08 ± 0.75 0.14 ± 0.35 0.990 0.725
       Men 0.06 ± 0.31 0.10 ± 0.22 0.24 ± 0.49* 0.147 0.196
  Genotype Interaction
        LA - 0.04 ± 0.43    - 0.13 ± 0.55    0.33 ± 0.39*         0.252                0.040
       NA 0.07 ± 0.39 0.16 ± 0.46     0.07 ± 0.52           0.955               0.987
Augmentation Index (AU)
 All participants 2.54 ± 10.28 -2.19 ± 11.12 -3.78 ± 17.23 0.047 0.821
       Women 5.02 ± 11.47 -4.27 ± 8.64 -2.35 ± 18.60 0.282 0.972
       Men 1.07 ± 9.63 -1.22 ± 12.81 -5.18 ± 1715 0.231 0.639
Genotype Interaction
      LA 1.24 ± 6,97 -0.80 ± 8.24 -4.98 ± 15.49 0.007 0.265
      NA 2304 ± 11.57 -1.10 ± 9.22 -3.91 ± 10.65 0.436 0.990
Results are expressed as mean ± SD (n=31). AU, arbitrary units; WW, white wine; WW+Tyr, 
white wine plus tyrosol (Tyr) capsules; LA, low activity group metabolizers; NA, normal 
activity group metabolizers. ANOVA adjusted by age, sex, smoking habits, acetylsalicylic acid 




3.5.1. Glucose, Lipids, and Inflammatory Biomarkers
Table 2 shows the changes in HDL-c after each intervention. A significant 
increase from their respective baselines was observed after the WW (p=0.027) and 
WW+Tyr (p<0.001) interventions, the latter remaining in men when analyses were 
stratified by gender (p<0.001). The increase in HDL-c after WW+Tyr was significant 
versus changes in the control group (p=0.025), and this significance remained in males 
(p< 0.001 vs control and p= 0.027 vs WW) and in the NA group (p=0.014 vs control) 
when analyses were stratified by gender or by PAS genotype, respectively. HDL-c 
increased in a dose-dependent manner with the content of alcohol plus Tyr administered 
in all populations (p=0.027 for linear trend), for men only (p=0.001 for linear trend), and 
with a borderline significance within the NA group (p=0.082) [20]. No differences by 
intervention group, gender, or PAS genotype were observed in total and LDL cholesterol, 
triglycerides, hsCRP, or glucose [20].
 Table 2. Changes in HDL cholesterol (mg/dL) after interventions
Results are expressed as mean ± SD (n=32). WW, white wine; WW+Tyr, white wine plus tyrosol 
(Tyr) capsules; LA, low activity group metabolizers; NA, normal activity group metabolizers. 
ANOVA adjusted by age, sex and smoking habits, LDL cholesterol at the beginning of the study, 
Interventions
p value for WW+Tyr
Control WW
WW+Tyr 
Tyr vs Control vs WW
Total -0.11 ± 5.98 1.62 ± 5.06* 3.11 ± 3.96† 0.025 0.417
Women 2.61 ± 5.11 3.05 ± 6.65 1.27 ± 3.91 0.794 0.697
Men -1.74 ± 5.99 0.77 ± 3.75 4.17 ± 3.68† < 0.001 0.027
Genotype interaction
LA 0.66 ± 9.86 3.35 ± 7.74 3.44 ± 3.20* 0.802 0.995
NA -0.38 ± 2.59 1.12 ± 2.29* 2.97 ± 4.70* 0.014 0.242
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and baseline levels. *P < 0.05, †P<0.001 versus its baseline. P value, significance for inter-
intervention comparisons.
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3.5.2. Vasodilation related markers
Table 3 show the changes in Hcy concentrations. Hcy increased after WW (p= 
0.049) and decreased after the WW+Tyr intervention (p= 0.041) in the total group. 
WW+Tyr decreased Hcy in both genders (not significantly). When changes among 
interventions were compared, the decrease after WW+Tyr was significant versus changes 
after WW (P=0.028). The latter trend remained in the NA group when stratified by PAS 
genotype (p=0.095). ET1 concentrations after interventions were: 2.2 ± 0.9, 2.3 ± 1.1 
ng/mL, and 2.0 ± 0.8 ng/mL, after water, WW, and WW+Tyr interventions respectively 
[20]. Concentrations of ET1 after WW+Tyr were significantly lower versus WW 
intervention (p=0.031). No differences were observed when analyses were stratified by 
gender. No differences by intervention group, gender, or PAS groups were observed in 
nitrate and nitrite values. 
Table 3. Homocysteine changes (µmol/L) after interventions
Interventions
p value for WW+Tyr
Control WW WW+Tyr vs Control vs WW
All participants - 0.07 ± 1.11 0.40 ± 1.11* -0.36 ± 0.97* 0.975 0.028
       Women -0.23 ± 1.20 0.72 ± 1.36 -0.61 ± 1.20 0.675 0.315
       Men 0.01 ± 1.11 0.20 ± 0.90 -0.24 ± 0.80 0.826 0.358
Genotype interaction
       LA 0.13 ± 0.58 0.50 ± 1.01 -0.26 ± 0.85 0.973 0.533
       NA -0.19 ± 1.45 0.43 ± 1.20 -0.47 ± 1.06 0.963 0.095
Results are expressed as mean ± SD (n=32). WW, white wine; WW+Tyr, white wine plus tyrosol 
(Tyr) capsules; LA, low activity group metabolizers; NA, normal activity group metabolizers. 
ANOVA adjusted by age, sex smoking, acetylsalicylic acid consumption, and baseline levels. *p 
< 0.05 versus its baseline; P value, significance for inter-intervention comparison
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3.5.3. Coagulation and fibrinolysis biomarkers
Table 4 shows the changes in ATIII after each intervention. ATIII increased after 
WW+Tyr compared to its baseline (p=0.005), the increase was significant versus changes 
after control (p=0.044) and WW (p=0.005) interventions. When the data were stratified 
by gender, a borderline increase (p=0.060) after WW+Tyr occured in males, the increase 
was significant versus changes after WW (p=0.002). Concerning PAS groups, after the 
WW+Tyr intervention, ATIII plasma concentrations increased versus its baseline 
(p=0.010) in the NA group. No differences by intervention group, gender, or PAS groups 
were observed in PAI and dimer D plasma concentrations.
Table 4. Changes in antithrombin III (mg/dL) after interventions
Interventions
p value for WW+Tyr










































Results are expressed as median (25th-75thpercentiles) (n=32). WW, white wine; WW+Tyr, white 
wine plus tyrosol (Tyr) capsules; LA, low activity group metabolizers; NA, normal activity group 
metabolizers. ANOVA adjusted by age, sex and smoking habits, and baseline levels. Prior to 
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statistical analysis, data were transformed using the following formula ln(x+1)). *P < 0.05, 
†P<0.01 versus its baseline; P value, significance for inter-intervention comparisons.
3.5.4. Gene expression
Figure 5 shows comparisons among percentage of changes in the expression of genes 
related to cardiovascular risk with significant changes in all populations. Subgroup 
changes are depicted in Boronat et al., 2019 [20]. CD40L expression decreased following 
WW+Tyr (p<0.001), the decrease was significant versus changes after control (p=0.041) 
and WW (p=0.003) interventions. When analyses were stratified by gender, CD40L 
decreased versus its baseline after WW+Tyr in both genders (p<0.05), the decrease was 
significant versus control (p=0.016) and WW (p=0.024) for males. Concerning PAS 
groups, in the NA group the CD40L expression decreased after WW+Tyr versus control 
(p=0.011) and WW(p=0.0.020) groups. The expression of P65/RELA decreased versus 
changes after WW intervention in all subjects (p=0.048). CFH expression increased 
versus its baseline in all subjects and among women (p<0.05) after WW intervention. 
After the WW+Tyr intervention, there was a decrease versus changes after WW 
intervention in all subjects (p=0.025). When analyses were stratified by gender, there was 
a decrease in males versus baseline after the WW+Tyr intervention (p=0.010) which was 
significant versus control (p= 0.013) and WW (p=0.048). iNOS increased after WW 
intervention (P=0.032), the increase was significant versus the decrease observed after 
WW+Tyr intervention in the all subjects (p=0.007) and among males (p=0.019). The 
expression of eNOS and VEGFA increased after the WW intervention (p=0.034 and 
p=0.045, respectively), and decreased after the WW+Tyr intervention versus changes 
after the WW intervention in all subjects (p=0.045). No changes were observed in 
expression of other genes which were evaluated. 
25
Figure 5. Changes in the expression of cardiovascular related risk genes. WW, white 
wine; WW+Tyr, white wine plus tyrosol capsules.
 
* p<0.05 versus water; ‡ p<0.05, ¥ 
p<0.001 versus white wine; $ p<0.05, £ p<0.001 versus its baseline.
4. Discussion
The present study reports occurange of endogenous bioconversion of Tyr into 
OHTyr in vivo and confirms the in vivo modulation of this reaction by variation in 
CYP2A6 and CYP2D6. Our findings enhance our understanding of the in vivo biological 
activity of Tyr and OHTyr. This activity goes beyond simple ROS scavenging, to being 
capable of modulating crucial signaling pathways. This data indicates that both Tyr per 
se and its endogenous conversion into OHTyr promote cardiovascular health benefits in 
humans. Ingestion of an enriched WW+Tyr improved endothelial function, plasma levels 
of HDL-c, Hcy, ET1, and ATIIII, and the expression of CD40L, p65/RELA, and CFH in 
PBMC. Addition of Tyr to WW abolished the increase in iNOS, eNOS, VEGFA, and CHF 
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observed after WW. Tyr seems the preferential phenol involved in benefits on RHI and 
AI, whereas OHTyr appears to be the leading phenol for explaining HDLc, Hcy, ATII 
systemic levels, and CD40L expression improvements. A schema of the possible 
interrelationships among these variables is depicted in Figure 6, and comparisons among 
changes after WW and WW+Tyr in Boronat et al., 2019 [20].
Figure 6. Interrelationship among tyrosol and its biotransformation into hydroxytyrosol 
with endothelial function and its risk factors. 1, tyrosol seems to be the main phenol 
involved in the direct improvement of reactive hyperemia (RHI) and arterial stiffness 
(AI). Its conversion to hydroxytyrosol (2), however, also improves endothelial function 
through an increase in HDL-c (3) and antithrombin III (ATIII) (4), and a decrease in 
homocysteine (Hcy) (5), endothelin 1 (ET1) (6), CD40L (7), and p65 (9) expressions. The 
increase in ATIII could be mediated by the decrease in Hcy (8) and both changes could 
improve endothelial function through a reduction in NFkB (p65-RElA) (9), potentiated by 
the CFH decrease (10), and in iNOS (11) that in turn contributes to ET1 reduction (12). 
Full lines depict the study findings, and dashed linesindicate related mechanisms.
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In the present report we show a novel biochemical mechanism by which foods 
rich in Tyr could be a source of OHTyr. OHTyr formation is of relevance since most 
healthy effects attributed to EVOO in the context of the MeDiet are attributed to the 
profile of monounsaturated fatty acids and to its content of OHTyr. The relevance of 
OHTyr in the MeDiet has been further supported with an independent association 
between high homovanillyl alcohol concentrations, a stable OHTyr metabolite, and a 
lower risk of CVD and total mortality in elderly individuals [14]. The effects of VOO, 
however, cannot be directly extrapolated to the effects of pure OHTyr or pure Tyr.  In this 
study, WW was chosen as matrix for performing the clinical studies for two reasons. First, 
wine alcohol content improves Tyr bioavailability [17]. Secondly, the content of phenolic 
compounds of WW is the lowest from among grape products (like red or sparkling wine) 
reducing confounding of interpretation. In this context, the coadministration of Tyr in the 
form of capsules and its bioconversion to OHTyr can be observed easily over the 
background of phenolic compounds already present in the white wine administered. In 
this study, the WW intervention allowed the determination of the OHTyr formation due 
to the ethanol, via dopamine oxidative metabolism, with the phenolic compounds present 
in the matrix (mainly Tyr); together estimated to be of 19% over baseline. In contrast, 
WW+Tyr resulted in a 283% increase compared to baseline of OHTyr recovery. This 
difference between WW and WW+Tyr interventions can, essentially, be attributed only 
to Tyr biotransformation to OHTyr. 
To the best of our knowledge, there is no data assessing the toxicological effects 
of high doses of Tyr. Based on OHTyr toxicology, EFSA has established a no-observed 
adverse effect level (NOAEL) of 50mg/kg/day. Due to the similarity of the molecules, 
we do not expect any harmful effects from the given dose of Tyr as it was far below the 
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OHTyr NOAEL. Nonetheless, toxicological studies may need to be performed to ensure 
Tyr safety [27].
Endothelial dysfunction is a predictor for CVD [25,28]. In our study RHI, a 
marker for the endothelium-dependent vasodilator function [29],  increased by a mean of 
0.176 AU after WW+Tyr. This value corresponds to a 0.103 AU when data are on a 
logarithmic scale (Ln-RHI). A 0.1 increase in Ln-RHI has been associated with a 21% 
decrease in CVD according a metanalysis that included 1602 individuals [30]. AI is a 
marker for arterial stiffness, an independent predictor of cardiovascular and 
cerebrovascular diseases, and a consequence of endothelial function impairment [31,32]. 
In our study, AI decreased after the WW+Tyr intervention. Thus, our data agree with 
previous reports concerning the benefits of polyphenol-rich VOO on endothelial function 
in humans [33]. 
As expected, HDL-c increased after both treatments in which moderate alcohol 
consumption was involved [34]. HDL protects endothelial function by preventing LDL 
oxidation [35]. Within the frame of the EUROLIVE Study we reported 1) a dose-
dependent increase of plasma HDL-c, a decrease in LDL oxidation [2], and an 
improvement of HDL functionality [36] with the phenolic content (mainly OHTyr and 
Tyr) of the olive oil administered and 2) the capacity of the OHTyr biological metabolites 
to bind to the HDL lipoprotein in a dose-dependent manner with the OHTyr content of 
the olive oil administered [36]. Together these impacts enhance HDL fluidity [36]  and 
protect HDL from oxidation, thus rendering the particle fully functional [35]. In 
agreement with our previous data [2], in the present study HDL-c increased in a dose-
dependent manner with the Tyr and OHTyr content of the beverage administered. 
We observed improvements in Hcy and ATIII after the WW+Tyr intervention. 
Hcy, a risk factor for CVD and deep vein thrombosis, promotes endothelial dysfunction 
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through several mechanisms including NFҡB activation [28]. Here we showed an 
increase in Hcy levels after the WW treatment, consistent with increases in Hcy levels 
after moderate alcohol and red/white wine consumption as previously described [37]. The 
addition of Tyr to WW abolished this increase in Hcy. Hcy also has prothrombotic effects 
[38]. Cerebrovascular disease patients with high urinary Hcy/creatinine ratio have been 
reported to have lower concentrations of ATIII [39]. Accordingly, we observed a 
concomitant decrease of ATIII as well as Hcy. ATIII, a pleiotropic molecule with anti-
coagulation and anti-inflammation effects, contributes to an adequate blood flow [40]. 
Flow perturbation mediates neutrophil recruitment and potentiates endothelial injury [41]. 
The anti-inflammatory properties of ATIII include the inhibition of neutrophil 
recruitment and NFҡB pathways [42]. NFҡB activation promotes that of the 
inflammatory mediator  iNOS [43]. Likewise, iNOS inhibition improves endothelium-
dependent vasodilatation in aged rats [44]. Hcy disrupts the angiogenesis of the 
microvascular endothelium through an increase of iNOS expression [45]. The anti-
inflammatory capacity of ATIII includes iNOS expression inhibition [46]. In agreement 
with the changes observed in Hcy and ATIII in our study, the increase in iNOS after WW 
was abolished after WW+Tyr treatment. In experimental models, Tyr, OHTyr, and their 
biological metabolites inhibit iNOS expression [47]. iNOS inhibition attenuates ET1 
levels [48]. In agreement with this, in our study, post-treatment ET1 concentrations after 
WW+Tyr decreased versus the WW ones, particularly in the NA group. 
As iNOS, soluble CD40L also induces endothelial dysfunction [49]. We have 
previously described a decrease in CD40L expression in vivo in healthy volunteers which 
was associated with the high phenolic content (mainly Tyr and OHTyr) of VOO [16].  
Consistent with this, in the present study, WW+Tyr reduced CD40L expression. Similar 
decreases occurred after wine and cocoa flavonoid intake [50,51]. We observed decreases 
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in p65 (RELA) and CFH after WW+Tyr. p65 (RELA) is a transcription factor belonging 
to the NFĸB family and its inactivation, like that of CFH, improves the inflammatory 
status [52]. CFH competes with C1q for binding to target surfaces [53], and C1q exerts 
inhibitory effects on pro-inflammatory gene expression by reducing NFҡB mediated 
transcription through a p65 decreased activation[54]. Thus, in our study we observed 
concomitant reductions in p65 and CFH expressions after WW+Tyr intervention. Red 
wine polyphenol extracts decrease both NFkB (p65) and iNOS expressions [55], and 
inhibition of p65 translocation by olive tree (Olea Europea L) methanolic extracts has 
been recently reported [56]. Tyr-4-sulfate prevents TNF-α-induced NF-κB signaling in 
endothelial cells by reducing p65 phosphorylation [57]. The WW+Tyr treatment 
eliminated the increase observed in the expression of p65/RELA, VEGFA, eNOS, and 
CFH after WW. At present there are no data from human in vivo studies concerning the 
effect of alcohol and wine on the expression of these genes. VEGF induces proangiogenic 
changes such as vessel dilatation and increased vascular permeability predominantly via 
eNOS [58], and VEGF inhibition decreases CFH in the eye and kidney [59]. 
Our findings confirm the involvement of CYP2A6 and CYP2D6 enzymes in the 
endogenous formation of OHTyr from Tyr in vivo in humans. The fact that individuals 
with low PAS have higher Tyr recoveries, and those with normal activity showed a higher 
OHTyr/Tyr ratio at the end of the WW+Tyr intervention confirms a role for genetic 
modulation of these enzymes in Tyr metabolism to OHTyr. Differences in the observed 
health effects following interventions, between LA and NA metabolizers, allowed the 
identification of which phenolic compound, Tyr or OHTyr, was preferentially involved 
in the changes observed. The fact that the increase in RHI, and the decrease in AI, after 
WW+Tyr occurred preferentially in the LA group, where Tyr recovery is high and 
OHTyr/Tyr ratio is low, indicates Tyr as the likely main responsible phenol for RHI and 
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AI improvements. Conversely, the fact that the decrease in Hcy and the increases in ATIII 
and HDL-c after the WW+Tyr treatment occurred particularly in the NA group, where 
OHTyr and OHTyr/Tyr recovery ratios are high, provides evidence that OHTyr is the 
main phenol involved in these improvements. Similarly, decreases in CD40L occurred 
particularly in the NA group suggesting OHTyr as the key phenol involved.
Our study has strengths and limitations. One strength is the crossover design 
which minimizes the role of possible confounding variables and between-subject 
variation. The similarity of matrices between WW and WW+Tyr treatments permitted us 
to assess the role of the exogenous Tyr administered and its bioconversion into OHTyr. 
One limitation is the sample size, particularly for women. The length of the study (6 
months) and the restricted inclusion criteria may have decreased study recruitment for 
both genders. Tyr and alcohol doses were higher in men than in women may contribute 
to the higher responsiveness to interventions in men. Although Tyr and OHTyr effects 
are influenced by PAS, not all of the variability in OHTyr and Tyr recoveries could be 
explained by variants assessed for CYP2A6 and CYP2D6 and used in the PAS. Besides, 
additional untested variants, and potential alternative enzymes contributing to variation, 
enzyme expression can be affected by further factors such as drugs, diet or hormones.  
We were unable to assess treatment interference due to dietary components or medication. 
The fact that participants were CVD risk individuals limits the extrapolation of the results 
to the general population. Whether additional or different effects would have been 
observed over longer periods is unknown, nevertheless, greater intervention periods could 
have compromised participants’ compliance.
In conclusion, ours is the first study to demonstrate the endogenous conversion of 
Tyr into OHTyr occurs in humans in vivo. This describes a new mechanism that could 
explain, in part, the potential benefits associated with moderate wine consumption and of 
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other Tyr rich components of our diet. Moreover, we have shown that both Tyr and its 
partial biotransformation to OHTyr promoted cardiovascular health-related benefits in 
humans after the intake of Tyr, in the context of real-life diet pattern with wine intake 
with meals. The study design allowed the health effects of individual phenols to be singled 
out from the dietary matrix in which they are built-in. Tyr bioconversion to OHTyr is 
modified by CYP2A6/CYP2D6 genetic polymorphisms, and therefore some individuals 
may benefit more than others from the biological activities of these antioxidants. The 
results obtained in the present work encourage further study of Tyr rich foods and/or Tyr 
supplements with other foods or beverages for added enhancement of the healthy 
bioactivities in vivo.
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